EDIT Editas Medicine, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650664 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.4%
TTM net income YoY63.9%
TTM EPS YoY77.0%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-151.7%
Net margin-145.0%
FCF margin-221.7%
EBITDA margin-147.5%
Returns
ROE-147.4%
ROA-34.3%
ROIC (approx.)—
Asset turnover0.24x
Leverage & solvency
Liabilities / assets61.5%
Debt / equity0.67x
Current ratio2.82x
Interest coverage-10.58x
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio18.0%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $40.52M | $32.31M |
| R&D expense | $89.95M | $199.25M |
| SG&A expense | $49.90M | $71.99M |
| Operating income | -$160.01M | -$251.15M |
| Interest expense | $2.13M | $0 |
| Income tax | $0 | $0 |
| Net income | -$160.06M | -$237.09M |
| EBITDA | -$154.73M | -$245.34M |
| EPS (basic) | -1.80 | -2.88 |
| EPS (diluted) | -1.80 | -2.88 |
| Weighted avg. shares (diluted) | 88.75M | 82.34M |
| Balance sheet | ||
| Cash & equivalents | $146.65M | $135.42M |
| Short-term investments | $0 | $138.37M |
| Receivables | $15.18M | $16.27M |
| Current assets | $163.90M | $289.31M |
| PP&E, net | $3.54M | $14.50M |
| Total assets | $186.53M | $341.59M |
| Current liabilities | $46.25M | $77.22M |
| Short-term debt | $5.00M | $5.00M |
| Long-term debt | $53.60M | $52.43M |
| Total debt | $58.60M | $57.43M |
| Total liabilities | $159.25M | $207.31M |
| Shareholders' equity | $27.29M | $134.27M |
| Net debt | -$88.04M | -$77.98M |
| Shares outstanding | 97.87M | 82.73M |
| Cash flow statement | ||
| Operating cash flow | -$165.24M | -$210.28M |
| Capital expenditure | $607,000 | $8.83M |
| Free cash flow | -$165.85M | -$219.11M |
| Investing cash flow | $138.67M | $162.15M |
| Financing cash flow | $40.47M | $56.03M |
| Depreciation & amortization | $5.28M | $5.81M |
| Stock-based compensation | $10.00M | $21.42M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.